About Cypherpunk Technologies Inc.
https://www.leaptx.comCypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer.
CEO
Douglas E. Onsi
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-21 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B
Price Target
About Cypherpunk Technologies Inc.
https://www.leaptx.comCypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $209K ▲ | $7.73M ▼ | $-25.97M ▼ | -12.43K% ▼ | $-0.08 ▲ | $-25.18M ▼ |
| Q2-2025 | $0 | $16.88M ▲ | $-16.64M ▼ | 0% | $-0.4 ▼ | $-16.64M ▼ |
| Q1-2025 | $0 ▼ | $15.92M ▼ | $-15.44M ▲ | 0% ▲ | $-0.37 | $-15.43M ▲ |
| Q4-2024 | $234K ▲ | $34.54M ▲ | $-40.17M ▼ | -17.17K% ▼ | $-0.37 ▲ | $-20.19M ▼ |
| Q3-2024 | $0 | $17.86M | $-18.18M | 0% | $-0.44 | $-18.35M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $174.14M ▲ | $294.82M ▲ | $52.61M ▲ | $242.22M ▲ |
| Q2-2025 | $18.13M ▼ | $20.04M ▼ | $14.32M ▲ | $5.72M ▼ |
| Q1-2025 | $32.71M ▼ | $34.88M ▼ | $14.04M ▼ | $20.84M ▼ |
| Q4-2024 | $47.25M ▼ | $49.12M ▼ | $14.08M ▼ | $35.05M ▼ |
| Q3-2024 | $62.82M | $65.05M | $16.09M | $48.95M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-25.97M ▼ | $-16.29M ▼ | $13.99M ▲ | $213K ▲ | $-2.09M ▲ | $-18.28M ▼ |
| Q2-2025 | $-16.64M ▼ | $-14.49M ▼ | $0 | $-119K ▼ | $-14.58M ▼ | $-14.49M ▼ |
| Q1-2025 | $-15.44M ▼ | $-14.48M ▲ | $0 | $-61K ▼ | $-14.54M ▲ | $-14.48M ▲ |
| Q4-2024 | $-15.43M ▲ | $-15.51M ▲ | $0 | $104K ▲ | $-15.57M ▲ | $-15.51M ▲ |
| Q3-2024 | $-18.18M | $-15.6M | $0 | $-66K | $-15.66M | $-15.6M |
Revenue by Products
| Product | Q1-2021 | Q4-2021 | Q3-2021 | Q2-2021 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Douglas E. Onsi
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-21 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : B